相关临床试验
119
18 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1854
进行中（未招募）
6
5.0%
已完成
53
44.5%
Enrolling By Invitation
1
0.8%
尚未招募
11
9.2%
招募中
26
21.9%
暂停
1
0.8%
终止
2
1.7%
Unknown
19
16.0%
暂无批准数据
- A new Landmark Perspective in Science marks the 50th anniversary of Robert C. Gallo's 1976 discovery of a human T-cell growth factor later named interleukin-2 (IL-2). - The discovery enabled long-term culture of human T cells, leading to identification of the first human retroviruses HTLV-1 and HTLV-2 and establishing human retrovirology. - The same capability proved critical to characterizing HIV as the cause of AIDS and to developing the HIV blood test, improving global blood supply safety. - IL-2 also underpinned cellular immunotherapy advances including tumor-infiltrating lymphocyte therapy and CAR-T cell therapy, with scientific exchange continuing in Venice in 2027.
- Researchers from Trinity College Dublin and University College Dublin demonstrated for the first time that dietary yeast beta-glucan reprograms bone marrow stem cells to enhance anti-tumor immune responses. - The supplement restored innate immunity in obese mice and reversed long-term immune memory defects that persist even after weight loss, a major unmet clinical challenge. - Yeast beta-glucan is already widely used as a food supplement with an excellent safety record, making it a realistic candidate for clinical translation. - The study, published in Cell Reports, showed efficacy across colorectal, skin, and breast cancer models in mice fed either standard or high-fat diets.
- A large study of nearly 4,000 Finnish children found that methylphenidate (Ritalin, Concerta) does not increase psychosis risk in ADHD patients and may actually provide protective effects when used long-term in children under 13. - Sustained methylphenidate treatment for three to four years in younger children appeared to lower the risk of developing psychotic conditions, challenging previous concerns about stimulant medications. - The research suggests that the known increased risk of psychosis in ADHD patients is likely due to shared genetic factors rather than medication effects, providing reassurance for parents and clinicians. - Questions remain about amphetamine-based ADHD medications like Adderall, which previous studies have linked to higher psychosis risk, particularly in older adolescents and adults.
- Ireland's Minister for Further and Higher Education launched Phase 2 of Precision Oncology Ireland (POI), the country's largest cancer research program focused on personalized cancer care. - The program represents a substantial increase in investment, scale and ambition compared to Phase 1, with enhanced clinical engagement and broader scientific scope. - POI-2 aims to embed research within standard cancer care and develop advanced computer simulations to design individualized diagnostic and treatment approaches for each patient. - The initiative brings together academics, industry partners, charities, and patients in a cross-sector collaborative model coordinated by University College Dublin's Systems Biology Ireland centre.
- AngioDynamics has enrolled the first patient in the RECOVER-AV clinical trial, evaluating the AlphaVac F1885 System for treating intermediate-risk pulmonary embolism across multiple international sites. - The multi-center study will assess safety and long-term functional outcomes in up to 20 hospital sites across Europe, Canada, and Hong Kong, following patients for 12 months with comprehensive cardiac assessments. - The trial builds on the device's existing FDA 510(k) clearance and CE Mark approval, aiming to generate evidence for broader global adoption of mechanical thrombectomy treatment. - Pulmonary embolism affects approximately 435,000 patients annually in the six largest EU countries, representing a significant unmet medical need for effective treatment options.
- Metsera's MET-233i demonstrated up to 8.4% placebo-subtracted weight loss at Day 36 in a Phase 1 trial of 80 participants with overweight or obesity. - The ultra-long acting amylin analog showed a 19-day half-life, supporting once-monthly dosing and potential combination with Metsera's GLP-1 receptor agonist MET-097i. - The drug exhibited favorable tolerability with no safety signals, positioning it as a potential first-in-class monthly multi-NuSH combination therapy. - Metsera plans to advance MET-233i in ongoing monotherapy and combination trials, with topline data expected in late 2025 and early 2026.
- Ireland has initiated MAGIC-I (Molecular and Genomic Interrogation of Childhood Cancer – Ireland), the country's first clinical genomics study in pediatric oncology, aiming to optimize treatment through advanced genetic profiling. - The five-year project will establish processes for comprehensive genomic analysis for all children and adolescents with cancer in Ireland, potentially enabling earlier diagnosis and personalized treatment approaches. - Developed through collaboration between Systems Biology Ireland, Children's Health Ireland, Precision Oncology Ireland, and industry partners, the study incorporates innovative concepts like digital twins and computational modeling.
